Ind-Swift Ltd - Stock Valuation and Financial Performance

BSE: 524652 | NSE: INDSWFTLTD | Pharmaceuticals & Drugs | Small Cap

Ind-Swift Share Price

18.30 1.40 8.28%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Ind-Swift

M-Cap below 100cr DeciZen not available

Ind-Swift stock performance -

mw4me loader
P/E Ratio (SA):
3.33
Market Cap:
99.1 Cr.
52-wk low:
6.5
52-wk high:
24.3

Is Ind-Swift Ltd an attractive stock to invest in?

1. Is Ind-Swift Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Ind-Swift Ltd is a average quality company.

2. Is Ind-Swift Ltd undervalued or overvalued?

The key valuation ratios of Ind-Swift Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Ind-Swift Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Ind-Swift Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Ind-Swift:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Ind-Swift Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -5.2%-11.1%-20.7%-27.5%-6.7%-2.5%-1.1%1.1%5.2%7.2%-
Value Creation
Index
-1.4NANANANANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 570417304263270289330356398411473
Sales YoY Gr.--26.8%-27.1%-13.6%2.6%7.1%14%8.1%11.7%3.3%-
Adj EPS -22.7-28.8-39.7-33.7-6.5-2.1-5.2-6.1-4.3-3.75.5
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 10.9-16.2-53.7-115.4-125.4-124.9-131.7-128.3-133-130.1-134.4
Adj Net
Profit
-114-145-200-183-35.1-11.3-28.1-33.1-23.3-20.330
Cash Flow from Ops. 10385.6-1066.71.342.834.683.250.273.1-
Debt/CF from Ops. 9.812.2-9.9156788.623.629.412.320.613.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -3.6%8.8%7.6%3.3%
Adj EPS NANANANA
BVPS-231.8%NANANA
Share Price 12.5% 27.3% 56.4% 172.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-70.1-421.3143.342.95.41.74.14.73.32.8-4.2
Op. Profit
Mgn %
-5.7-16.8-51.6-24.92.93.77.111.611.410.28.9
Net Profit
Mgn %
-20-34.8-65.7-69.4-13-3.9-8.5-9.3-5.9-4.96.3
Debt to
Equity
14.7-15.5-4.1-1.7-1.6-1.5-1.4-1.5-1.4-1.4-
Working Cap
Days
537686799602355317291300281280110
Cash Conv.
Cycle
325391450195-44-89-101-102-67-51-269

Recent Performance Summary

Sales growth is good in last 4 quarters at 16.27%

Return on Equity is Poor

Sales growth has been subdued in last 3 years 7.64%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Ind-Swift Ltd.

Standalone Consolidated
TTM EPS (₹) 5.5 5.5
TTM Sales (₹ Cr.) 473 473
BVPS (₹.) -134.4 -134.4
Reserves (₹ Cr.) -739 -739
P/BV -0.14 -0.14
PE 3.33 3.33
From the Market
52 Week Low / High (₹) 6.50 / 24.29
All Time Low / High (₹) 1.86 / 88.15
Market Cap (₹ Cr.) 99.1
Equity (₹ Cr.) 10.8
Face Value (₹) 2
Industry PE 48.2

Management X-Ray of Ind-Swift:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *73.4673.4673.4342.8142.8142.8142.8142.8142.8142.81
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Ind-Swift

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales569.80417.17304.33263.05269.81289.03329.52356.06397.71410.96
Operating Expenses 603.92487.10461.28328.46263.52278.28306.18314.68352.36368.93
Manufacturing Costs39.9523.4719.4719.9524.0327.4528.4430.1050.8649.06
Material Costs458.49353.43220.48166.03154.16159.95187.73186.52211.02218.04
Employee Cost 45.1339.2736.7738.7944.6746.3348.9351.1757.7563.75
Other Costs 60.3570.93184.56103.6940.6644.5541.0946.8932.7338.08
Operating Profit -34.12-69.93-156.95-65.406.3010.7523.3441.3745.3542.03
Operating Profit Margin (%) -6.0%-16.8%-51.6%-24.9%2.3%3.7%7.1%11.6%11.4%10.2%
Other Income 12.801.8712.5113.6814.578.4422.3815.2223.5511.85
Interest 76.7639.9318.9716.3211.463.7735.1952.1857.1659.76
Depreciation 26.2639.3636.3535.7334.6333.9733.5932.7032.0728.67
Exceptional Items 000-259.61-28.1526.746.40-1.210.7360.58
Profit Before Tax -124.34-147.36-199.77-363.37-53.388.19-16.66-29.49-19.6026.04
Tax -8.77-2.230.170.890.7502.460.320.420
Profit After Tax -115.56-145.13-199.94-364.27-54.138.19-19.12-29.82-20.0226.04
PAT Margin (%) -20.3%-34.8%-65.7%-138.0%-20.1%2.8%-5.8%-8.4%-5.0%6.3%
Adjusted EPS (₹)-23.0-28.8-39.7-67.3-10.01.5-3.5-5.5-3.74.8
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 101.70-46.18-246.16-611.01-679.37-676.74-713.12-695.16-720.32-704.70
Share Capital 24.2724.2724.2725.0310.8310.8310.8310.8310.8310.83
Reserves 77.43-70.45-270.43-636.04-690.20-687.57-723.95-706-731.15-715.53
Minority Interest0000000000
Debt932.15910.431,042.911,048.291,055.241,008.551,014.771,020.03984.81757.97
Long Term Debt585.10541.41671.65664.77681.20644.67644.21644.17619.30403.11
Short Term Debt347.05369.02371.25383.52374.04363.88370.56375.86365.51354.86
Trade Payables191.35150.26175.38161.76180.12198.83226.22232.02203.91234.73
Others Liabilities 164.61213.3288.6670.0156.7767.7873.77114.69163.36361.21
Total Liabilities 1,389.811,227.831,060.78669.06612.77598.42601.65671.57631.76649.21

Fixed Assets

Gross Block559.58565.68572.52576.38576.33589.92601.49607.40630.13637.42
Accumulated Depreciation119.45162.02198.37234.07265.65299.37331.83363.39394.63420.95
Net Fixed Assets440.12403.66374.14342.31310.68290.56269.66244.01235.50216.46
CWIP 4.443.893.672.2200013.06929.73
Investments 45.1945.1245.1243.9043.9141.2624.0670.3164.3553.73
Inventories253.36113.3790.9439.0645.444952.4162.8569.5889.35
Trade Receivables440.14485.48380.33108.4883.5075.5694.17107.9590.62104.58
Cash Equivalents 17.9016.9817.399.113.6819.7216.7628.9916.1813.33
Others Assets188.67159.33149.19123.98125.56122.33144.59144.41146.51142.03
Total Assets 1,389.811,227.831,060.78669.06612.77598.42601.65671.57631.76649.21

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 102.7385.57-105.796.721.3442.7934.6083.1950.2073.05
PBT -124.34-147.36-199.77-363.37-53.388.19-19.12-28.29-20.34-34.54
Adjustment 107.1090.75168.51321.1573.1221.3252.6888.1277.9485.23
Changes in Working Capital 120.11142.19-74.5448.95-18.4113.271.0323.68-6.9822.36
Tax Paid -0.13000000-0.32-0.420
Cash Flow From Investing Activity -13.76-5.52-4.01-4.30-2.73-13.71-11.35-16.71-18.42-29.35
Capex -14.63-5.73-4.18-4.45-2.86-13.99-12.37-20.13-19.48-30.12
Net Investments 00.01000001.6000
Others 0.870.200.170.150.140.281.011.811.060.77
Cash Flow From Financing Activity -88.87-80.97110.21-10.71-4.04-13.03-26.20-54.25-44.60-46.56
Net Proceeds from Shares 6.68000000000
Net Proceeds from Borrowing 00000000-74.19-207.89
Interest Paid -30.87-37.49-21.68-15.26-1.15-3.59-32.73-52.92-58.27-63.69
Dividend Paid 0000000000
Others -64.68-43.48131.894.56-2.90-9.446.53-1.3387.87225.03
Net Cash Flow 0.11-0.910.41-8.28-5.4316.05-2.9612.23-12.81-2.85
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)-112.51N/AN/AN/AN/AN/AN/AN/AN/AN/A
ROCE (%)-4.27N/AN/AN/AN/AN/AN/AN/AN/AN/A
Asset Turnover Ratio0.410.320.270.310.420.480.560.580.620.65
PAT to CFO Conversion(x)N/AN/AN/AN/AN/A5.22N/AN/AN/A2.81
Working Capital Days
Receivable Days256400513334129100921009085
Inventory Days18515912189576055576069
Payable Days132176270371405432413448377367

Ind-Swift Ltd Stock News

Ind-Swift Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Ind-Swift on 28-Mar-2024 16:01 is ₹18.30.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Ind-Swift stood at ₹99.12.
The latest P/E ratio of Ind-Swift as of 28-Mar-2024 16:01 is 3.33.
The latest P/B ratio of Ind-Swift as of 28-Mar-2024 16:01 is -0.14.
The 52-week high of Ind-Swift is ₹24.29 and the 52-week low is ₹6.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ind-Swift is ₹472.9 ( Cr.) .

About Ind-Swift Ltd

Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.

Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.

Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, ointments, injectables, liquids & dry syrup (all latest formulations with a marketing network.

Business areas of the company are:

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include the following:Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence

The company is also in health Publications- With the maiden issue in September, 2002; Ind-Swift’s Health Publication TRENDZ brings the latest in medical field to the medical fraternity. Routinely published four times a year, each issue of TRENDZ is devoted to important contemporary healthcare issues and medical issues of a particular specialty.

Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and researchers.

  • A well accepted expertise in NDDS, in India and the world over.
  • A US patent for Clarie OD, with a market size of $300 million.
  • Another patent for Fexofenadine ODT with a market size of $2.5 billion.
  • Development of 10 new molecules with a market size of $6 billion.

Ind Swift’s efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.

Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases.

Awards/ Achievements

  • Ranked as one of the most promising pharmaceutical group in India by Express Pharma Pulse.
  • All India achievers award as legend in Business house category.
  • An ISO 9001, 2000 company.
  • Achieved Pharma Pulse award as fastest growing & most promising pharmaceutical company for three successive years.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.